SCHEMBL22008480

SCHEMBL22008480

CC(C)Oc1ccccc1[C@H](C(=O)O)N1CC(C(=O)N2CC[C@@H](CCc3ccc4c(n3)NCCC4)C2)C1

nearest known ligand 0.57

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 20/20 0.57
ITGAV P06756 20/20 0.57
ITGB5 P18084 20/20 0.57
ITGB1 P05556 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22008481 1.00 ITGB3 (0.57) ITGB3ITGAVITGB5ITGB1
SCHEMBL20481439 1.00 ITGB3 (0.57) ITGB3ITGAVITGB5ITGB1
SCHEMBL20481436 1.00 ITGB3 (0.57) ITGB3ITGAVITGB5ITGB1
SCHEMBL22008479 0.96 ITGB3 (0.56) ITGB3ITGAVITGB5ITGB1
SCHEMBL20481445 0.96 ITGB3 (0.56) ITGB3ITGAVITGB5ITGB1
SCHEMBL22008474 0.96 ITGB3 (0.56) ITGB3ITGAVITGB5ITGB1
SCHEMBL20481448 0.96 ITGB3 (0.56) ITGB3ITGAVITGB5ITGB1
SCHEMBL22009087 0.91 ITGAV (0.47) ITGB3ITGAVITGB5ITGB1
SCHEMBL20481157 0.91 ITGAV (0.47) ITGB3ITGAVITGB5ITGB1
SCHEMBL22009084 0.91 ITGAV (0.47) ITGB3ITGAVITGB5ITGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827621-B2 Inhibitors of (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2023-11-28 US disclosed
US-11827621-B2 Inhibitors of (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2023-11-28 US disclosed
US-20210276975-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2021-09-09 US disclosed
US-11046669-B2 Inhibitors of (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2021-06-29 US disclosed
US-11040955-B2 Inhibitors of (alpha-v)(beta-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2021-06-22 US disclosed
US-20200157075-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2020-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210276975-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV ITGB3 11/4885ITGAV 3/4885ITGB5 15/4885
US-11827621-B2 Inhibitors of (α-v)(β-6) integrin ITGB6, ITGA6, ITGAV ITGB3 12/4885ITGAV 3/4885ITGB5 15/4885
US-20200157075-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV ITGB3 11/4885ITGAV 3/4885ITGB5 15/4885
US-11040955-B2 Inhibitors of (alpha-v)(beta-6) integrin ITGB6, ITGA6, ITGAV ITGB3 11/4885ITGAV 3/4885ITGB5 15/4885
US-11046669-B2 Inhibitors of (α-v)(β-6) integrin ITGB6, ITGA6, ITGAV ITGB3 12/4885ITGAV 3/4885ITGB5 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.